Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$9.79
$1.72(17.57%)
At close: 4:00 PM EDT
$9.79
$1.72(17.57%)
Day’s Range― - ―
52-Week Range$3.94 - $18.14
Previous CloseN/A
Volume2.32M
Average Volume (3M)1.97M
Market Cap
$1.24B
Enterprise Value$1.02K
Total Cash (Recent Filing)$131.95M
Total Debt (Recent Filing)$83.77M
Price to Earnings (P/E)9.0
Beta1.34
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding72,388,310
10 Day Avg. Volume1,277,528
30 Day Avg. Volume1,970,668
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside237.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$68.00M
Bulls Say, Bears Say
Bulls Say
First-to-market ApprovalRegulatory first‑mover status creates a durable competitive advantage: as the sole approved therapy for TA‑TMA and the first lectin‑pathway inhibitor, YARTEMLEA can establish clinical standard‑of‑care relationships, pricing and hospital pathways that support recurring hospital channel revenues and future label expansions over the next 2–6 months and beyond.
Early Commercial TractionRapid initial uptake across transplant centers and immediate distributor shipments show the commercial model is operational. Early multi‑account ordering and quick logistics indicate scalable supply and adoption, supporting a sustainable revenue ramp and an improving cash flow profile as hospital access and coding progress continue.
Large Non-dilutive FundingA $240M upfront plus milestone structure materially de‑risks near‑term funding need, preserves shareholder equity versus dilutive alternatives, and finances both the YARTEMLEA commercial scale‑up and ongoing pipeline development, extending runway and enabling deliberate R&D and commercialization investments over the coming months.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$95M TTM highlights that core operations still consume cash. Even with early product revenue and upfront proceeds, continued burn forces careful capital allocation, may require further financing if commercial ramp slows, and constrains investments in sales, marketing and trials.
Negative Shareholders' EquityNegative equity signals an impaired capital base and weaker balance sheet flexibility. Even as debt has been reduced, persistent negative equity can limit secured borrowing, increase cost of capital, and reduce strategic optionality for partnerships, acquisitions or large commercial investments during the next several quarters.
Earnings Volatility From ConvertiblesEmbedded derivative remeasurements tied to convertible notes create material quarter‑to‑quarter swings unrelated to operations. With substantial remaining convertible principal and ongoing interest expense, these mark‑to‑market effects and cash interest obligations complicate forecasting, stress reported earnings reliability, and can impair investor confidence over the medium term.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $3.94 and its highest was $18.14 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $1.24B.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 87 days.
How were Omeros Corporation’s earnings last quarter?
Omeros Corporation released its earnings results on Aug 12, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.418.
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is 0.02.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 72,388,310 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Omeros Corporation reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 26.55%.
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (237.08% Upside)
$33.00 (237.08% Upside)
Blogger Sentiment
Bullish
OMER Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 13.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Negative
20 days / 200 days
Momentum
172.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.01%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
OMER Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$33.00
▲(237.08% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.73% Insiders
7.87% Mutual Funds
11.17% Other Institutional Investors
63.08% Public Companies and
Individual Investors